For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Shipments of Ensure to Resume in Late May: Abbott Japan
April 4, 2011
- CHMP to Assess Benefit-Risk Balance of Pioglitazone
April 4, 2011
- Asahi Kasei Licenses XIAFLEX from Auxilium
April 4, 2011
- MREAC Calls For “Consideration”in Post-disaster MR Activities
April 4, 2011
- Kowa, MEDRx Announce Agreement for Etodolac Patch
April 4, 2011
- Recruiting Is the Lifeblood of Any Company
April 4, 2011
- Meiji Seika Licenses Ziprasidone from RaQualia
April 4, 2011
- Vaccination with Prevnar, ActHIB to Resume April 1
April 4, 2011
- R-Tech Ueno Licenses Unoprostone to Sucampo
April 4, 2011
- Nomura Securities Expects Peak Sales of ¥130 Bil. for Latuda
March 28, 2011
- Chuikyo Meetings to Be Postponed Due to Disaster
March 28, 2011
- Takeda Suspends Shipment of All ASKA Pharma Products
March 28, 2011
- Astellas Settles Dispute over Tarceva Patents with Teva
March 28, 2011
- JAMS Cancels 2011 General Assembly
March 28, 2011
- Fuso's Replacement Fluid in Short Supply
March 28, 2011
- Sales by Member Companies Up 0.2% in 2010: JCROA
March 28, 2011
- Most Scientific Meetings Postponed or Cancelled
March 28, 2011
- Maintain Electric Power to Ensure Stable Drug Supply: FPMAJ
March 28, 2011
- Drugstore Sales Up 3.5% in FY2010: JACDS
March 28, 2011
- Change in Prescription Form Proposed by JSGM President
March 28, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…